Form 144 Spyre Therapeutics, Inc. Filed by: Sloan Sheldon
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Spyre (SYRE) PT Raised to $107 at Stifel
May 5, 2026 4:26 PM EDTStifel analyst Alex Thompson raised the price target on Spyre (NASDAQ: SYRE) to $107.00 (from $92.00) while maintaining a Buy rating.
The analyst comments "Following best-in-class UC PoC data for SPY001 (a4B7), SYRE is well-positioned heading into additional PoC cohorts for... More
